Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World January 19, 2011 Jon Cartwright	Modified protein binders give shortcut to drugs The method, which involves attaching polypeptides to the binders, could help reduce the work required to develop protein binders into safer drugs.
Chemistry World March 4, 2015 Philip Ball	Program ready to weed out tough drug leads A method for reliably predicting how well a candidate drug molecule will bind to its target receptor would allow libraries of molecules to be screened on the computer, without having to synthesize them all.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Chemistry World June 23, 2015 Derek Lowe	Missing the target There are enzymes that no mustard has ever cut, to steal a phrase from science fiction author James Blish. Phosphatases, the flip side of kinase activity, are a perfect example.
Chemistry World January 7, 2014 Derek Lowe	Is there a drug for that? One hears a lot about the concept of 'druggability' in pharmaceutical research. If that concept has any meaning (and it probably does), then the implication is that there must be such a thing as 'undruggability'. So what does that look like?
Chemistry World February 14, 2011 Catherine Bacon	New hepatitis C drug Scientists in the UK have developed a compound to combat the hepatitis C virus that could be taken as a pill.
Chemistry World February 18, 2011 Carol Stanier	Speed dating for pharmaceuticals A simple analysis of hydrogen bond strengths finds the best crystallisation partners for drugs, say UK scientists.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
Chemistry World October 17, 2011 Andy Extance	Water erodes 'lock and key' drug model US researchers have dealt a severe blow to the idea of a single 'hydrophobic effect' that can help explain how all drugs dock with proteins.
Bio-IT World September 2006 Kevin Davies	Pfizer's Global Survey of Pharmacological Space The pharma blends knowledge, computational chemistry and research informatics to build a unified database. Gathering all the data in one place offered greater control for indexing and data retrieval and management, enabling Pfizer scientists to perform global mapping.
Chemistry World October 25, 2007	Elusive Drug Target Finally Seen Scientists have captured an atomic-scale picture of a receptor protein from a family that is the target of thousands of drugs.
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool December 28, 2005 Stephen D. Simpson	AstraZeneca, Reloaded In an attempt to shore up a soft pipeline, AstraZeneca has gotten very busy looking for partners. Investors, this is not the most attractive stock in the sector, but not a horrible pick, either.
Bio-IT World December 10, 2002 Arielle Emmett	Locus Focus Cheminformatics company Locus Discovery is a technology darling and an entrepreneur's dream, but it faces a dilemma over how much of its proprietary drug discovery software and data to reveal.
Chemistry World April 27, 2011 Carol Stanier	Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool December 31, 2009 Brian Orelli	Make Money Even When Drugs Fail Biotech growth potential without as much risk can come from innovations that help drugmakers discover new drugs.
BusinessWeek December 29, 2010 Kelley & Cortez	AstraZeneca's Risky Bet on Drug Discovery Instead of acquisitions and diversification, AstraZeneca is determined to find new pills in its own labs.
Chemistry World January 13, 2008 Ananyo Bhattacharya	Unexpected Effects of Drug Combinations Medicines that use a combination of several drugs can sometimes produce unexpected effects in patients. Now, a team of scientists think they have figured out how that can happen.
BusinessWeek April 11, 2005 Arlene Weintraub	Drawing A Bead On Side Effects Drug makers are figuring out ways to make some old remedies such as Propulsid safer.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
Chemistry World May 31, 2009 Nina Notman	The natural approach to winning at drug discovery High throughput drug screening is often described as a casino, with the odds stacked on the side of success as long as a big enough library is used.
Chemistry World February 12, 2009 Simon Hadlington	Mystery receptor's binding partner uncovered For decades scientists have puzzled over the role of the sigma-1 receptor, a protein found in almost all mammalian cells, including the nervous system.
Chemistry World July 21, 2011 Elinor Richards	Cell Control to Change Cell Function US scientists can now control the reactions occurring inside cells.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
Pharmaceutical Executive February 1, 2006 Ron Feemster	Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets.
Chemistry World July 11, 2008 Manisha Lalloo	Side-effects study opens up new drug leads Existing drugs could be used to treat a broader range of diseases, according to scientists in Germany and Denmark, who have predicted drug targets by using side-effects data on medication labels.
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
Chemistry World October 2, 2012 Fiona McKenzie	Protein sorting within cells US scientists have used magnetic nanoparticles with specific ligands to latch on to and visualize specific proteins in living cells.
Chemistry World March 17, 2009 Phillip Broadwith	Electronic 'nose' could shed light on sense of smell Korean researchers have combined human smell receptors with nanotechnology to create a new kind of 'bio-electronic nose'
Chemistry World November 18, 2010 Ned Stafford	New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
Chemistry World August 27, 2013 Ian Le Guillou	A golden answer to drug competition The golden ratio, first noted around 300BC by Euclid in his mathematical treatise The Elements, can be found across geometry, nature and now even pharmacology. The golden ratio could point the way for a simple method of determining competition between drugs.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Bio-IT World September 11, 2003 Mark D. Uehling	Fishing Chips The next generation of protein microarrays from the likes of Protometrix and Molecular Staging may threaten the early leads of Biacore and Ciphergen -- and work so well that drug companies won't want them.
Chemistry World September 29, 2015	Navigating chemical space How big is chemistry? I don't mean how important is it, or how many people do it, but rather, how many molecules are there that we could make?
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
BusinessWeek June 2, 2011 Kresge & Connolly	A New Pricing Game for Drugmakers in Europe Germany's new rules tying pharmaceutical prices to greater efficacy is worrying companies.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Bio-IT World April 15, 2003 Mark D. Uehling	Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials.